A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.
The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.
A user shared their experience using Dutasteride for hair loss, alongside a regimen of Minoxidil, Finasteride, and RU58841. They reported no major shedding or sexual side effects, but experienced mild acne when increasing the Dutasteride dose, and noted their hair condition remained stable.
Charts show how long Finasteride and Dutasteride stay in the blood, explaining why 0.5 mg Finasteride is less effective than 1 mg. Dutasteride accumulates over time, leading to gradual results compared to the immediate effects of Finasteride.
A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
After switching from finasteride to dutasteride, the user experienced a 25% increase in total testosterone and a 150% increase in free testosterone, with side effects like brain fog and nipple tingling. The user plans to consult a lab for accuracy and adjust the dutasteride dosage to manage side effects.
User reports almost 2 months on DUT and MIN for hair loss with positive results. Treatment includes 0.5mg dut (morning), 5mg oral min (night), and vitamin D and B12 supplements.
The user switched from finasteride to dutasteride 0.5mg daily two years ago and has experienced hair maintenance and slight thickening without side effects. The user's libido increased after switching, and they are not using minoxidil.
The conversation discusses hair loss and the impact of testosterone and DHT levels, with suggestions to monitor these levels and consider vitamin D supplementation. Treatments mentioned include finasteride and possibly minoxidil.
The user switched from finasteride to dutasteride for hair loss treatment and is experiencing shedding after 4 months. Another person suggests that this is not unusual and recommends giving it more time.
Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.
Hair density improved using topical dutasteride, minox, keto, and 3.5% fluridil for 6 months. Better results when hair is dry, but still unsatisfied when wet.
Reducing scalp DHT doesn't directly correlate with preventing hair miniaturization, as different follicles have varying sensitivity levels. Dutasteride at 0.5 mg and 2.5 mg shows minimal visual difference in hair regrowth, with side effects being a consideration for higher doses.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
Topical finasteride reduces scalp DHT effectively, with a suggested application of 1.5ml of 0.03% daily. It binds to scalp enzymes, potentially requiring daily or every other day application for sustained results.
The user reports significant hair regrowth after 200 days using dutasteride and minoxidil, attributing changes to hair dye. Others doubt the authenticity and discuss treatment effectiveness and side effects.
After switching from finasteride to dutasteride, the user noticed new hair growth and experienced manageable shedding. They reported feeling great on dutasteride with minimal side effects, using Cialis occasionally for libido issues.
The user experienced initial hair regrowth with topical dutasteride and minoxidil but later faced significant hair shedding, leading to doubts about the effectiveness of topical dutasteride. They plan to continue the treatment for a year and may switch to oral finasteride if no improvement is seen.
User discusses hair loss treatment progress using Dutasteride for 2 years, RU58841 for 5 months, and oral Minoxidil for 1 year. Some users share side effects and experiences with these treatments.
The conversation discusses the use of dutasteride (0.5 mg daily) for hair loss, with additional treatments like minoxidil, derma rolling, and nizoral shampoo. The user reports positive progress over two years with no significant side effects, emphasizing the importance of consistency and patience.
The user experienced mental side effects from both oral and topical finasteride and is considering trying dutasteride or liposomal topical finasteride. They are concerned about potential worsening of hair loss if they quit dutasteride.
A user is seeking information on clinics in Toronto offering dutasteride mesotherapy as an alternative to oral dutasteride while trying to conceive. They are looking for recommendations and information.
A 25-year-old male using Dutasteride, oral Minoxidil, and Ketoconazole shampoo is experiencing increased hair shedding and vellus hair growth along the hairline. Concerns are raised about whether this is a seasonal shed or a potential setback.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
User is experiencing scalp itch and hair loss despite using Nizoral, Minoxidil, derma rolling, and Finasteride for 6 months. They are considering switching to Dutasteride.